



TissueGene, Inc. to Present at Windhover Information's "The Start-Up Forum 2005"

GAITHERSBURG, MD., May 18, 2005 – TissueGene, Inc. has announced that it will be presenting at 9:55am on May 20th at Windhover Information's "The Start-Up Forum 2005," taking place May 18-20, 2005 at the Cambridge Marriott in Boston, MA. TissueGene's product candidates can be used to address a range of orthopedic disease and injury, including various types of arthritis, cartilage damage, bone fractures and spinal cord injuries. According to the CDC, arthritis and chronic joint problems impact over 70M Americans with nearly 60% of the population 65 years or older impacted by arthritis. Furthermore, as the average age of the population increases the number of individuals affected by orthopedic diseases is predicted to grow dramatically. TissueGene's CEO Dr. Kwan Hee Lee and Director of Business Development J. Kelly Ganjei will both be attending and Mr. Ganjei will present the company at the event. A copy of the presentation will be posted on the company's Web site www.tissuegene.com after May 20. "Regenerating cartilage is what is really needed in diseases such as OA, and unfortunately for those suffering from the disease the treatments available today are focused on symptomatic relief," said Dr. Lee. "TissueGene's cell mediated approach will be a first mover in the market towards regenerating hyaline cartilage without invasive surgical procedures."

A former professor and orthopedic surgeon at the Inha University Medical School, Dr. Lee and his team discovered how to use cell therapy as a mechanism to deliver a clinically significant and continuous stream of growth factor(s) to the site of injury and ultimately grow human cartilage. He then built a company around this technology with a goal of commercializing cell therapies for those suffering from osteoarthritis and other musculoskeletal diseases.

About TissueGene, Inc.

TissueGene, Inc. is a Maryland-based company focused on developing a proprietary suite of regenerative orthopedic therapeutic products directed to the treatment and regeneration of damaged cartilage, bones, and nerves. The company's core technology employs a form of cell mediated therapy to deliver therapeutic proteins to damaged tissue, which initiates rapid and permanent repair of injured tissue without the need for surgery. TissueGene's first product, TG-C, is focused on the regeneration of cartilage and is in the process of entering its Phase I clinical trial at Mt Sinai Hospital in Baltimore. The first indication for TG-C will be focused on patients with osteoarthritis of the knee. For more information, visit www.tissuegene.com.